Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
North Central Cancer Treatment Group National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00376675 |
RATIONALE: Methylphenidate may help relieve fatigue caused by cancer. It is not yet known whether methylphenidate is more effective than a placebo in relieving fatigue and improving quality of life in patients with cancer.
PURPOSE: This randomized phase III trial is studying methylphenidate to see how well it works in treating patients with fatigue caused by cancer.
Condition | Intervention | Phase |
---|---|---|
Fatigue Unspecified Adult Solid Tumor, Protocol Specific |
Drug: methylphenidate hydrochloride Drug: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Double-Blind, Placebo Control |
Official Title: | Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study |
Estimated Enrollment: | 140 |
Study Start Date: | February 2008 |
Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm I: Experimental
Patients receive oral methylphenidate daily on days 1-28.
|
Drug: methylphenidate hydrochloride
Given orally
|
Arm II: Placebo Comparator
Patients receive oral placebo daily on days 1-28.
|
Drug: placebo
Given orally
|
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to disease stage (0, I, or II vs III or IV), level of fatigue at baseline (4-7 vs 8-10), concurrent biological therapy (yes vs no), concurrent chemotherapy (yes vs no), and concurrent radiotherapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.
PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed cancer, except for any of the following:
History of cancer-related fatigue, as defined by a score of ≥ 4 on a fatigue numerical analogue scale (0-10)
PATIENT CHARACTERISTICS:
No psychiatric disorder, including any of the following:
None of the following medical conditions for which the use of methylphenidate is contraindicated:
PRIOR CONCURRENT THERAPY:
More than 4 weeks since prior major surgery
No concurrent administration of any of the following:
Tricyclic antidepressants
Investigator: | Amit Sood, MD | Mayo Clinic |
Investigator: | Shaker R. Dakhil, MD, FACP | Cancer Center of Kansas, PA - Wichita |
Investigator: | Charles L. Loprinzi, MD | Mayo Clinic |
Study ID Numbers: | CDR0000495148, NCCTG-N05C7 |
Study First Received: | September 13, 2006 |
Last Updated: | December 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00376675 |
Health Authority: | United States: Federal Government |
fatigue unspecified adult solid tumor, protocol specific |
Signs and Symptoms Dopamine Fatigue Methylphenidate |
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Physiological Effects of Drugs Central Nervous System Stimulants Dopamine Agents Central Nervous System Agents Pharmacologic Actions |